1-phenyl-4-(3-phenyl-propyl)-piperazine | 136534-55-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-phenyl-4-(3-phenyl-propyl)-piperazine
• 英文别名: LASSBio-724；1-Phenyl-4-(3-phenylpropyl)piperazine
• CAS: 136534-55-9
• 化学式: C₁₉H₂₄N₂
• 分子量: 280.413
• InChiKey: BBEVNYGQARSQPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (3-fluoropropyl)benzene 在 三(五氟苯基)硼烷 、 N,N-二异丙基乙胺 作用下， 以 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 18.08h， 生成 1-phenyl-4-(3-phenyl-propyl)-piperazine
  参考文献：
  名称：

  通过伪卤化物中间体对脂肪族氟化物进行亲核取代

  摘要：

  已经报道了用多种亲核试剂将脂肪族氟化物官能化的方法。通过使用甲硅烷基化的假卤化物TMS-OMs或TMS-NTf 2热力学驱动碳-氟键裂解，导致形成TMS-F和捕获的脂族假卤化物中间体。氟化物/假卤化物的交换速率和该中间体的稳定性使得在直链脂肪族氟化物中几乎看不到末端氟化物的重排。将有机氟化物位置转化为假卤化物基团的能力允许各种亲核试剂容易地进行亲核攻击。亲核试剂的后期引入还允许偶联伴侣具有广泛的功能基团耐受性。在存在其他烷基卤化物的情况下观察到选择性的烷基氟化物甲磺酰化，从而允许正交合成策略。

  DOI：

  10.1002/chem.201806272

文献信息

• pH-Mediated Selective Synthesis of N-Allylic Alkylation or N-Alkylation Amines with Allylic Alcohols via an Iridium Catalyst in Water
  作者：Nianhua Luo、Yuhong Zhong、Hongling Shui、Renshi Luo

  DOI：10.1021/acs.joc.1c01930

  日期：2021.11.5

  Amination of allylic alcohols is an effective approach in the facile synthesis of N-allylic alkylation or N-alkylation amines. Recently, a series of catalysts were devised to push forward this transformation. However, current synthetic methods are typically limited to achieve either N-allylic alkylation or N-alkylation products via a certain catalyst. In this article, a pH-mediated selective synthesis of N-allylic

  烯丙醇的胺化是一种简便合成N-烯丙基烷基化或N-烷基化胺的有效方法。最近，设计了一系列催化剂来推动这一转变。然而，目前的合成方法通常仅限于通过某种催化剂获得N-烯丙基烷基化或N-烷基化产物。在本文中，揭示了通过铱催化剂以水作为环境友好溶剂，选择性合成N-烯丙基烷基化或N-烷基化胺与烯丙基醇，从而实现N-烯丙基烷基化和N-烷基化产物的高产率。此外，具有低催化剂负载的克级实验提供了获得用于合成抗真菌药物萘替芬的独特入口的潜力。
• [EN] INTERMEDIATES AND PROCESSES FOR PREPARATION OF VORTIOXETINE<br/>[FR] INTERMÉDIAIRES ET PROCÉDÉS DE PRÉPARATON DE VORTIOXÉTINE
  申请人：LAKSHMI PRASAD ALAPARTHI

  公开号：WO2017216805A1

  公开（公告）日：2017-12-21

  The present invention relates to new intermediate compounds useful in the preparation of phenyl-piperazine compounds such as Vortioxetine and process for their preparation. The present invention also relates to process for preparing Vortioxetine or its pharmaceutically acceptable salts using said intermediates.

  本发明涉及新的中间化合物，可用于制备苯基哌嗪类化合物，如伏地苯和其制备方法。本发明还涉及利用上述中间体制备伏地苯或其药用可接受盐的方法。
• N-PHENYL-N'-PHENYLPROPYLPIPERAZINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF
  申请人：Zeria Pharmaceutical Co., Ltd.

  公开号：EP1090913A1

  公开（公告）日：2001-04-11

  N-Phenyl-N'-phenylpropylpiperazine derivatives represented by general formula (1) (wherein R1 is lower alkyl; R2 is lower alkoxy; and R3 is cyano, carboxyl or indolecarbonyl); drugs containing the same; and a process for the preparation thereof. The compounds exhibit potent α1-adrenergic receptor blocking activity and are useful in the prevention and treatment of hypertension, congestive heart failure, myocardial ischemia, arrhythmia, angina pectoris, urinary disturbance and frequent urination due to prostatic hypertrophy, and so on.

  通式(1)代表的N-苯基-N'-苯基丙基哌嗪衍生物（其中R1为低级烷基；R2为低级烷氧基；R3为氰基、羧基或吲哚羰基）；含有这些衍生物的药物；及其制备方法。这些化合物具有强效的α1-肾上腺素能受体阻断活性，可用于预防和治疗高血压、充血性心力衰竭、心肌缺血、心律失常、心绞痛、前列腺肥大引起的排尿障碍和尿频等。
• Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent alpha 1A/D-Adrenergic receptor blocking properties
  作者：Luiz A.S. Romeiro、Marcos da Silva Ferreira、Leandro L. da Silva、Helena C. Castro、Ana L.P. Miranda、Cláudia L.M. Silva、François Noël、Jéssica B. Nascimento、Claudia V. Araújo、Eduardo Tibiriçá、Eliezer J. Barreiro、Carlos A.M. Fraga

  DOI：10.1016/j.ejmech.2011.04.032

  日期：2011.7

  We described herein the discovery of 1-(2-(benzo[d] [1,3]dioxol-6-yl)ethyl)-4-(2-methoxyphenyl) piperazine (LASSBio-772), as a novel potent and selective alpha 1A/1D adrenoceptor (AR) antagonist selected after screening of functionalized N-phenylpiperazine derivatives in phenylephrine-induced vasoconstriction of rabbit aorta rings. The affinity of LASSBio-772 for alpha 1A and alpha 1B AR subtypes was determined through displacement of [(3)H]prazosin binding. We obtained Ki values of 0.14 nM for the alpha 1A-AR, similar to that displayed by tamsulosin (K(i) = 0.13 nM) and 5.55 nM for the alpha 1B-AR, representing a 40-fold higher affinity for alpha 1A-AR. LASSBio-772 also presented high affinity (K(B) = 0.025 nM) for the alpha 1D-AR subtype in the functional rat aorta assay, showing to be equipotent to tamsulosin (K(B) = 0.017 nM). (C) 2011 Elsevier Masson SAS. All rights reserved.
• Novel 1-phenylpiperazine and 4-phenylpiperidine derivatives as high-affinity .sigma. ligands
  作者：Richard A. Glennon、Mamoun Y. Yousif、Abd M. Ismaiel、Mahmoud B. El-Ashmawy、J. L. Herndon、James B. Fischer、Alfred C. Server、Kathleen J. Burke Howie

  DOI：10.1021/jm00116a003

  日期：1991.12

  Sigma-receptors may represent an exciting new approach for the development of novel psychotherapeutic agents. Unfortunately, many of the commonly used sigma-ligands lack selectivity (e.g., many bind at phencyclidine or dopamine receptors) or suffer from other serious drawbacks. Recently, we described a series of 2-phenylaminoethanes that bind at sigma-receptors with high affinity and selectivity. Because there is evidence that 1-phenylpiperazines can structurally mimic the 2-phenylaminoethane moiety, we prepared a series of 1-phenylpiperazines and related analogues and incorporated structural features already shown to enhance the sigma-binding of the 2-phenylaminoethanes. Several of these derivatives bind at sigma-receptors with high affinity (K(i) = 1-10 nM) and lack appreciable affinity for phencyclidine and dopamine receptors. In as much as certain of these agents structurally resemble the high-affinity, but nonselective, sigma-ligand haloperidol, and because they bind with 10 times the affinity of haloperidol, we have apparently identified what appears to be the primary sigma-pharmacophore of that agent.